来曲唑与枸橼酸氯米芬治疗不明原因不孕症的比较:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项随机对照试验共2647例不明原因不孕症患者,比较来曲唑与枸橼酸氯米芬的卵巢刺激效果;每患者阳性妊娠试验率来曲唑组24% vs 枸橼酸氯米芬组23%(合并RR 1.08,95%CI 0.85-1.36),临床妊娠、活产、自然流产及双胎妊娠均无显著差异;来曲唑组平均血清雌二醇显著低于枸橼酸氯米芬组。
要点
- 每患者阳性妊娠试验率来曲唑组24% vs 枸橼酸氯米芬组23%,合并RR 1.08(95%CI 0.85-1.36),无显著差异。
- 临床妊娠、活产、自然流产、双胎妊娠的合并RR均无显著差异。
- 来曲唑组平均血清雌二醇显著低于枸橼酸氯米芬组。
核心结论
- 尽管受异质性限制,不明原因不孕症女性卵巢刺激研究显示来曲唑与枸橼酸氯米芬的临床结局无差异。
研究设计与样本
- 系统综述与荟萃分析,检索Ovid-MEDLINE、EMBASE、Scopus、Cochrane系统综述数据库、Cochrane对照试验注册库、效果评价摘要数据库及ClinicalTrials.gov。
- 纳入8项比较枸橼酸氯米芬与来曲唑的随机对照试验,共2647例不明原因不孕症患者。
主要发现
- 每患者阳性妊娠试验率来曲唑组24% vs 枸橼酸氯米芬组23%,合并RR 1.08(95%CI 0.85-1.36),研究间异质性I=60.8%。
- 临床妊娠合并RR 1.15(95%CI 0.71-1.85),无显著差异。
- 活产合并RR 0.94(95%CI 0.83-1.08),无显著差异。
- 自然流产合并RR 0.92(95%CI 0.61-1.38),无显著差异。
- 双胎妊娠合并RR 0.81(95%CI 0.39-1.68),无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究间存在显著异质性(I=60.8%)。
- 结论受异质性限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the clinical effectiveness, as determined by positive pregnancy test, of letrozole compared with clomiphene citrate for ovarian stimulation in patients with unexplained infertility. DATA SOURCES: We conducted a systematic review and meta-analysis of data from electronic databases including Ovid-MEDLINE, EMBASE, Scopus, Cochrane Database of Systematic Reviews, Cochrane Register of Controlled Trials, Database of Abstracts of Reviews of Effects, and ClinicalTrials.gov. METHODS: We searched for concepts of unexplained infertility, letrozole, clomiphene citrate, and clinical outcomes including pregnancy and live birth. Studies were included if they were randomized controlled trials (RCTs) comparing clomiphene citrate with letrozole in patients with unexplained infertility. Eight RCTs including 2,647 patients with unexplained infertility were included. Primary outcome was positive pregnancy test per patient. Secondary outcomes included positive pregnancy test per cycle, clinical pregnancy, live birth, spontaneous miscarriage, twin gestation, mean serum estradiol (E2), endometrial thickness, and number of dominant follicles. The Cochrane Q test and Higgin's I were used to assess heterogeneity. Random effects models were used to obtain pooled relative risks (RR) and 95% CIs. TABULATION, INTEGRATION, AND RESULTS: In analysis per patient, there was no significant difference in positive pregnancy test between patients treated with letrozole compared with clomiphene citrate (24% vs 23%, pooled RR 1.08, 95% CI 0.85-1.36). Significant heterogeneity was noted between studies (I=60.8%). There were no significant differences in clinical pregnancy (pooled RR 1.15, 95% CI 0.71-1.85), live birth (pooled RR 0.94, 95% CI 0.83-1.08), spontaneous miscarriage (pooled RR 0.92, 95% CI 0.61-1.38), or twin gestation (pooled RR 0.81, 95% CI 0.39-1.68). Mean serum E2 was significantly lower in the letrozole group than in the clomiphene citrate group. CONCLUSION: Although limited by heterogeneity, studies of ovarian stimulation in women with unexplained infertility show no difference in clinical outcomes between letrozole and clomiphene citrate.
引用
- Eskew AM, Bedrick BS, Hardi A, et al. Letrozole Compared With Clomiphene Citrate for Unexplained Infertility: A Systematic Review and Meta-analysis. Obstet Gynecol. 2019. PMID: 30741800. doi:10.1097/AOG.0000000000003105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。